(Q74683283)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

main subject

piperacillin/tazobactam

1 reference

F Marra

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R Reynolds

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Stiver

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

E Bryce

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

K Sleigh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

L Frighetto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

C MacDougall

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

P Jewesson

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

Diagnostic Microbiology and Infectious Disease

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

355-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with haematological malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Therapy of soft tissue infections with piperacillin/tazobactam

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2897%2900239-3

7 January 2021

10.1016/S0732-8893(97)00239-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9635910%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference